StreetAlpha.app
Home › Stocks › DYN

Dyne Therapeutics, Inc. (DYN)

Healthcare
$15.50
▼ −3.31%
LAST CLOSE · NOV 20

Dyne Therapeutics develops drug candidates for genetic neuromuscular diseases using its FORCE delivery platform. It last closed at $15.50 on Nov 20, down 3.31% on the day. The next earnings report for DYN is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, DYN reported EPS of -$1.06. Over its last 8 reports the stock moved an average of 6.6% the session after earnings. Over the last 12 months DYN insiders bought $315K of stock on the open market and sold $168.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is DYN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DYN.

Key Stats

Last 12 months
Results
Net income
−$604.9M
EPS (diluted)
−$3.62
Free cash flow
−$568.8M
Valuation
Market cap
$2.9B
187.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$913.2M
At Sep 30
Debt
$200.0M
At Sep 30
Shareholder equity
$930.9M
Shares outstanding
187.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$149.3M−$149.3MFY2021FY2022: −$168.1M−$168.1MFY2022FY2023: −$235.9M−$235.9MFY2023FY2024: −$317.4M−$317.4MFY2024FY2025: −$446.2M−$446.2MFY2025

From DYN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$1.06
Quarter ended Sep 2026
Year ago EPS
-$0.76
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.88Dec '24Mar 2025: -$1.05Mar '25Jun 2025: -$0.97Jun '25Sep 2025: -$0.76Sep '25Dec 2025: -$0.73Dec '25Mar 2026: -$0.73Mar '26Jun 2026: -$1.08Jun '26Sep 2026: -$1.06Sep '26Latest -$1.06
Revenue by quarter
Not enough quarters on file yet.
How DYN moved after its last 8 reports
Average move the session after a report ±6.6%
Nov 5, 2026Time not announced−6.4%
Jul 29, 2026After the close+2.5%
May 11, 2026Time not announced+4.8%
Mar 2, 2026Time not announced+3.4%
Jan 12, 2026Time not announced−1.7%
Nov 5, 2025After the close−12.9%
Jul 28, 2025After the close−1.2%
May 8, 2025Time not announced+20.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DYNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DYN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DYN

Technical Analysis

DYN · as of the Nov 20 close · updated each morning
Downtrend

The stock is 10% below its 20 day and 7% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot S1 at $15.11, and the nearest resistance the Pivot at $15.80.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$27.3052 week high+76.1%
$20.56100 day average+32.6%
$19.27200 day average+24.3%
$17.0820 day average+10.2%
$16.73Swing high (Oct 21)+7.9%
$16.5550 day average+6.8%
$16.18Pivot R1+4.4%
$15.80Pivot+1.9%
$15.50Last close
$15.11Pivot S1−2.5%
$14.93Swing low (Oct 6)−3.7%
$14.0052 week low−9.7%
Indicators
RSI (14)39.10Weak, oversold below 30Neutral
MACD-0.25Below its signal lineBearish
Stochastic4.0Near the bottom of its rangeOversold
ADX (14)19.5No clear trend
Williams %R-97.5Oversold below −80, overbought above −20Oversold
CCI (20)-122.9Oversold below −100, overbought above 100Oversold
Rate of change−14.2%Change over 10 sessionsBearish
ATR (14)$0.94Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DYN

What happened before

See how DYN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DYN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DYN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DYNHow many large options trades hit DYN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

DYN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲187 buying vs 94 selling
  • ▲Held by funds +12.3 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding270247+9.3%
In funds' top 1054+25.0%
Held by funds114.0%101.7%+12.3 pts
New / increased60 / 12745 / 88+40.6%
Reduced / sold out59 / 3576 / 29−10.5%
Put/call ratio0.22––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DYN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DYN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$315K8 buys · 1 insider
Sold$168.8M42 sales · 6 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $76K2026-03 bought $118K2026-03 sold $15.7M2026-04 sold $36.9M2026-05 bought $79K2026-05 sold $2.1M2026-06 bought $78K2026-06 sold $23.6M2026-07 sold $24.5M2026-08 sold $65.4M2026-09 sold $248K2026-10 bought $40K2026-11 sold $174KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 13John CoxCEO & PresidentSale plan5,513$16.82$93K
Nov 13Erick LuceraCFOSale plan1,991$16.82$33K
Nov 13Douglas KerrHead of R&D and CMOSale plan2,604$16.82$44K
Nov 13Johanna Friedl-NadererChief Commercial OfficerSale plan231$16.82$4K
Oct 2Brian S PosnerDirectorBuy2,500$16.00$40K
Sep 8John CoxCEO & PresidentSale plan5,658$18.88$107K
Every insider buy and sale for DYN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DYN insider trades →

From SEC Form 4 filings by DYN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DYN is in one of them and how their past DYN trades turned out.

DYN in the AI portfolios
Loading…

DYN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DYN in an article yet. Here's the latest on the wider market.

DYN in the news

About Dyne Therapeutics

Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops drug candidates for muscle diseases caused by genetic changes. Its FORCE platform attaches a payload, such as an oligonucleotide or enzyme, to an antibody fragment that binds to a receptor found on muscle cells, aiming to carry treatments to muscle tissue and the central nervous system. The company's candidates target conditions including Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy and Pompe disease. Its candidates are still in clinical trials and not yet sold, with patients as the intended end users.

Headquarters
Waltham, MA